Last update 30 Mar 2025

MVT-5873

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
5B1-(sLeA)-therapeutic, Anti-CA19.9 antibody, anti-sialyl Lewisa antibody
+ [6]
Target
Action
inhibitors
Mechanism
CA19.9 inhibitors(Carbohydrate antigen 19-9 inhibitors)
Active Indication
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic Ductal AdenocarcinomaPhase 2
United States
27 Mar 2024
Advanced Bile Duct CarcinomaPhase 2
United States
13 Nov 2019
Liver metastasesPhase 2
United States
13 Nov 2019
Metastatic colon cancerPhase 2
United States
13 Nov 2019
Metastatic Colorectal CarcinomaPhase 2
United States
13 Nov 2019
Pancreatic CancerPhase 2
United States
13 Nov 2019
Small Cell Lung CancerPhase 1
United States
26 Jan 2019
Non-Small Cell Lung CancerPhase 1
United States
23 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Neoplasms | Pancreatic Cancer
CA19-9 Positive
9
xqoxfygqze(hevvkpgsen) = GI toxicity (abdominal pain/cramps/diarrhea/nausea) and G1-2 infusion reactions zinfbcfcpn (znqcvjodgh )
Positive
01 Jun 2018
Phase 1
25
ufjlqvafjp(sqmlwjglhk) = most were low grade and included GI toxicity (abdominal pain/cramps/diarrhea/nausea) ykpxvknxgf (zcigyxrjny )
Positive
30 May 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free